1 |
Lee, K.Y., Yuk, S.H., 2007. Polymeric protein delivery systems. Prog. Polym. Sci. 32, 669-697.
DOI
|
2 |
Lian, T., Ho, R.J., 2001. Trends and developments in liposome drug delivery systems. J. Pharm. Sci. 90, 667-680.
DOI
|
3 |
Manosroi, A., Khanrin, P., Werner, R.G., Gotz, F., Manosroi, W., Manosroi, J., 2010. Entrapment enhancement of pepetide drugs in niosomes. J. Microencapsul. 27, 272-280.
DOI
|
4 |
Meyenburg, S., Lilie, H., Panzner, S., Rudolph, R., 2000. Fibrin encapsulated liposomes as protein delivery system: Studies on the in vitro release behavior. J. Control. Release 69, 159-168.
DOI
|
5 |
Mokhtar, M., Sammour, O.A., Hammad, M.A., Megrab, N.A., 2008. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int. J. Pharm. 361, 104-111.
DOI
ScienceOn
|
6 |
van Winden, E.C., 2003. Freeze-drying of liposomes: theory and practice. Meth. Enzymol. 367, 99-110.
DOI
|
7 |
Vandana, M., Sahoo, S.K., 2009. Optimization of physicochemical parameters influencing the fabrication of protein-loaded chitosan nanoparticles. Nanomedicine (Lond) 4, 773-785.
DOI
|
8 |
Wang, W., 2005. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 289, 1-30.
DOI
|
9 |
Werle, M., Bernkop-Schnurch, A., 2006. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30, 351-367.
DOI
|
10 |
Blume, G., Cevc, G., 1990. Liposomes for the sustained drug release in vivo. Biochim. Biophys. Acta 1029, 91-97.
DOI
|
11 |
Crowe, J.H., Tsvetkova, N.M., Oliver, A.E., Leidy, C., Ricker, J., Crowe, L.M., 2006. Stabilization of liposomes by freeze-drying: lessons from nature. In: Gregoriadis, G. (Ed.), Liposome Technology, Vol. I: Liposome Preparation and Related Techniques, 3rd Ed., Informa Healthcare, USA.
|
12 |
Debs, R.J., Fuchs, H.J., Philip, R., Brunette, E.N., Duzgunes, N., Shellito, J.E., Liggitt, D., Patton, J.R., 1990. Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor alpha in rats. Cancer Res. 50, 375-380.
|
13 |
Gabizon, A., Martin, F., 1997. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumors. Drugs 54, 15-21.
|
14 |
Jeong, U.H., Jung, J.H., Davaa, E., Park, S.J., Myung, C.S., Park, J.S., 2009. Effect of drug loading on the physicochemical properties and stability of cationic lipid-based plasmid DNA complexes. J. Kor. Pharm. Sci. 39, 339-343.
과학기술학회마을
DOI
|
15 |
Katayama, K., Kato, Y., Onishi, H., Nagai, T., Machida, Y., 2003. Double liposomes: hypoglycemic effects of liposomal insulin on normal rats. Drug Dev. Ind. Pharm. 29, 725-731.
DOI
ScienceOn
|
16 |
Kim, J.K., Choi, S.H., Kim, C.O., Park, J.S., Ahn, W.S., Kim, C.K., 2003. Enhancement of polyethylene glycol (PEG)-modified cationic liposome-mediated gene deliveries: effects on serum stability and transfection efficiency. J. Pharm. Pharmacol. 55, 453-460.
DOI
ScienceOn
|
17 |
Kim, J.Y., Kim, J.K., Park, J.S., Byun, Y., Kim, C.K., 2009. The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials 30, 5751-5756.
DOI
|